Joel Neal, MD, PhD
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC 2220 MC 5826 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5800
- Academic Offices
Personal Information Tel (650) 725-3081Alternate Contact Traci Foster Administrative Assistant Tel Work 650-725-3081Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Thoracic Oncology
- Thoracic Oncology
- Lung Cancer
- Medical Oncology
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2010) |
| Medical Education: | Feinberg School of Medicine - Northwestern University IL (05/2004) |
| Fellowship: | Dana-Farber Cancer Institute MA (08/2010) |
| Residency: | Beth Israel Deaconess Medical Center MA (06/2007) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2007) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Non-small cell lung cancer (NSCLC) has historically been treated with combination chemotherapy. Over the last few years, molecular testing of NSCLC has revealed the presence of driving oncogenic mutations in a subset of tumors of adenocarcinoma histology, including EGFR, KRAS, and ALK. While chemotherapy is still effective for these patients, targeted therapies appear to be more specific with fewer side effects. For example, erlotinib treatment of EGFR mutant tumors results in better response rates and progression-free survival times than chemotherapy, and the investigational drug crizotinib is targeted against tumors harboring ALK translocations. My clinical and research interest is to apply evolving technologies to the diagnosis, characterization, and individualized treatment of NSCLC.
Clinical Trials
- Recruiting Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
- Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
- Recruiting Molecular Analysis of Thoracic Malignancies
- Recruiting Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
- Recruiting A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Publications
- A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013; (2): e17-8
- Aflibercept in lung cancer. Expert Opin Biol Ther. 2013; (1): 115-20
- A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012; (10): 1602-8
- Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2012; (18): 2280-2
- First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics. 2012: 337-45
- Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; (17): 2046-54
Help